title: WT1 peptide therapy for a patient with chemotherapy-resistant salivary gland cancer.
abstract: Wilms' tumor (WT1) protein is one of the most promising target antigens for cancer immunotherapy. In fact, clinical responses, such as growth stabilization or shrinkage of tumor with immunological responses, have been reported in patients vaccinated with WT1 peptide. Here, we performed WT1 peptide-based immunotherapy for a patient with chemotherapy-resistant salivary gland cancer, whose histologic type was carcinoma ex pleomorphic adenoma. The patient with its pulmonary metastasis, refractory to chemotherapy, was intradermally injected with 3 mg of WT1 peptide emulsified with Montanide ISA51 adjuvant at one-week intervals for 12 weeks. The considerably rapid growth of tumor was inhibited after WT1 vaccination, and stable disease, lasting three months, was achieved. Concomitantly, immunological responses, i.e. an increase in frequencies of WT1 tetramer(+) CD8(+)T cells and delayed type hypersensitivity response, were detected after the vaccination. These results indicate the potential of WT1 peptide-based immunotherapy for the treatment of chemotherapy-resistant salivery gland cancer.
authors.affiliation: Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Ehime, Japan.
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Shirakata
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Oka
authors.forename: Sumiyuki
authors.initials: S
authors.lastname: Nishida
authors.forename: Naoki
authors.initials: N
authors.lastname: Hosen
authors.forename: Akihiro
authors.initials: A
authors.lastname: Tsuboi
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Oji
authors.forename: Ayako
authors.initials: A
authors.lastname: Murao
authors.forename: Hidetaka
authors.initials: H
authors.lastname: Tanaka
authors.forename: Shin-Ichi
authors.initials: S
authors.lastname: Nakatsuka
authors.forename: Hidenori
authors.initials: H
authors.lastname: Inohara
authors.forename: Haruo
authors.initials: H
authors.lastname: Sugiyama
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012468:Salivary Gland Neoplasms / Q000188:drug therapy*; D025721:WT1 Proteins / Q000737:chemistry / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D025721:WT1 Proteins